Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535–54.

Article  PubMed  Google Scholar 

Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Prim. 2021;7:3.

Article  PubMed  Google Scholar 

Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–37.

Article  CAS  PubMed  Google Scholar 

Hiddinga BI, Raskin J, Janssens A, Pauwels P, Van Meerbeeck JP. Recent developments in the treatment of small cell lung cancer. Eur Respir Rev. 2021;30:210079.

Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021;32:698–709.

Article  CAS  PubMed  Google Scholar 

Yin YP, Ma LY, Cao GZ, Hua JH, Lv XT, Lin WC. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. Acta Pharmacol Sin. 2022;43:2119–27.

Yin YP, Shi WH, Deng K, Liu XL, Li H, Lv XT, et al. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer. Acta Pharmacol Sin. 2021;42:1298–310.

Article  CAS  PubMed  Google Scholar 

Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.

Article  CAS  PubMed  Google Scholar 

Chan CY, Tan KV, Cornelissen B. PARP inhibitors in cancer diagnosis and therapy. Clin Cancer Res. 2021;27:1585–94.

Article  CAS  PubMed  Google Scholar 

Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773–91.

Article  PubMed  Google Scholar 

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345–57.

Article  CAS  PubMed  Google Scholar 

Passiglia F, Reale ML, Cetoretta V, Parlagreco E, Jacobs F, Listi A, et al. Repositioning PARP inhibitors in the treatment of thoracic malignancies. Cancer Treat Rev. 2021;99:102256.

Article  CAS  PubMed  Google Scholar 

Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, et al. The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer. Front Oncol. 2020;10:565820.

Article  PubMed  PubMed Central  Google Scholar 

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Sun T, Meng Z, Wang L, Li M, Chen J, et al. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett. 2021;503:197–212.

Article  CAS  PubMed  Google Scholar 

Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, et al. Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study. J Thorac Oncol. 2021;16:1403–14.

Article  CAS  PubMed  Google Scholar 

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-naive extensive-stage small cell lung cancer: a phase 2 randomized study. Clin Cancer Res. 2021;27:3884–95.

Article  CAS  PubMed  Google Scholar 

Martire S, Banaszynski LA. The roles of histone variants in fine-tuning chromatin organization and function. Nat Rev Mol Cell Biol. 2020;21:522–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talbert PB, Henikoff S. Histone variants on the move: substrates for chromatin dynamics. Nat Rev Mol Cell Biol. 2017;18:115–26.

Article  CAS  PubMed  Google Scholar 

Frey A, Listovsky T, Guilbaud G, Sarkies P, Sale JE. Histone H3.3 is required to maintain replication fork progression after UV damage. Curr Biol. 2014;24:2195–201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–82.

Article  CAS  PubMed  Google Scholar 

Yuen BT, Knoepfler PS. Histone H3.3 mutations: a variant path to cancer. Cancer Cell. 2013;24:567–74.

Article  CAS  PubMed  Google Scholar 

Filipescu D, Muller S, Almouzni G. Histone H3 variants and their chaperones during development and disease: contributing to epigenetic control. Annu Rev Cell Dev Biol. 2014;30:615–46.

Article  CAS  PubMed  Google Scholar 

Park SM, Choi EY, Bae M, Kim S, Park JB, Yoo H, et al. Histone variant H3F3A promotes lung cancer cell migration through intronic regulation. Nat Commun. 2016;7:12914.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomes AP, Ilter D, Low V, Rosenzweig A, Shen ZJ, Schild T, et al. Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization. Cancer Cell. 2019;36:402–17. e13

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa M. Review of arsenic toxicity, speciation and polyadenylation of canonical histones. Toxicol Appl Pharmacol. 2019;375:1–4.

Article  CAS  PubMed  Google Scholar 

Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, et al. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009;8:1197–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Wang H, Tse E, Li H, Sun H. Cell cycle-dependent uptake and cytotoxicity of arsenic-based drugs in single leukemia cells. Anal Chem. 2018;90:10465–71.

Article  CAS  PubMed  Google Scholar 

Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling. Mol Cancer Ther. 2015;14:23–30.

Article  CAS  PubMed  Google Scholar 

Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, et al. Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res. 2012;18:3366–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu X, Wang H, Li H, Hu X, Zhang Y, Guan X, et al. S-Dimethylarsino-glutathione (darinaparsin(R)) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells. Chem Commun (Camb). 2019;55:13120–3.

Article  CAS  Google Scholar 

Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, et al. Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. J Natl Cancer Inst. 2016;108:djw122.

Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.

Article  CAS  PubMed  Google Scholar 

Reddy D, Bhattacharya S, Shah S, Rashid M, Gupta S. DNA methylation mediated downregulation of histone H3 variant H3.3 affects cell proliferation contributing to the development of HCC. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166284.

Article  CAS  PubMed  Google Scholar 

Li MX, Wang D, He JH, Chen LX, Li H. Bcl-X-L: a multifunctional anti-apoptotic protein. Pharmacol Res. 2020;151:104547.

Wang ZQ, Fan M, Candas D, Zhang TQ, Qin LL, Eldridge A, et al. Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression. Dev Cell. 2014;29:217–32.

Article  PubMed  PubMed Central  Google Scholar 

Chan JM, Quintanal-Villalonga A, Gao VR, Xie Y, Allaj V, Chaudhary O, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39:1479–96. e18.

Article  CAS  PubMed